UPDATE 1-FDA staff finds no new safety problems with Glaxo's asthma drug

March 17 (Reuters) - GlaxoSmithKline Plc's respiratory treatment for chronic breathing problems did not show any new safety problems while being tested to treat asthma, a preliminary review by U.S. Food and Drug Administration staff found.